Chronic Kidney Disease (CKD) Market in 8MM – Market Outlook, Unmet Needs, Market Assessment and Forecast (2023-2030)

Chronic Kidney Disease Market – Report Overview

Pacific Business Consulting’s “Chronic Kidney Disease (CKD) Market in 8MM – Market Outlook, Unmet Needs, Market Assessment and Forecast (2023-2030)” report offers a comprehensive understanding of chronic kidney disease, encompassing historical and projected market size data, along with market trends, market drivers, market barriers and unmet medical needs in the Eight Major Markets (8MM) of the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and China.

The market size for chronic kidney disease (CKD) reached US$5.3 billion across the 8 Major Markets (8MM) in 2022 and is projected to experience a Compound Annual Growth Rate (CAGR) of over 8% during the forecast period from 2023 to 2030. Chronic kidney disease, also known as chronic renal disease, is characterized by a gradual loss of kidney function over time, resulting in the accumulation of excess fluid and waste in the body. In its early stages, CKD is mostly asymptomatic, but symptoms worsen as the disease progresses, eventually leading to kidney failure.

CKD occurs when both kidneys are damaged sufficiently to impede the removal of metabolic products from the body and the ability to maintain mineral balance. Different diagnostic tests and treatments are required for each stage of CKD. Although there is no cure for CKD, available treatments can slow down its progression. In advanced stages of the disease, CKD patients are advised to undergo renal replacement therapy (RRT), which includes renal dialysis and kidney transplantation. RRT helps sustain life, regulate blood pressure, balance electrolytes for heart and muscle function, and support the production of vitamin D and red blood cells in CKD patients.

Recently approved therapies for CKD include FARXIGA (dapagliflozin), approved in the US, Europe, and Japan for CKD treatment in adults with and without type 2 diabetes (T2D). INVOKANA (canagliflozin) received FDA approval in 2019 to reduce the risk of end-stage kidney disease, worsening kidney function, cardiovascular death, and hospitalization for heart failure in adults with type II diabetes and diabetic kidney disease. Both dapagliflozin and canagliflozin are SGLT2 inhibitors. KERENDIA was approved in the US in 2021 and in Europe and Japan in 2022 for CKD and type II diabetes. JYNARQUE (tolvaptan), a selective vasopressin V2-receptor antagonist, has been approved for adults with autosomal dominant polycystic kidney disease (ADPKD) in multiple countries.

Key players in the CKD segment include Novo Nordisk A/S, Boehringer Ingelheim, ProKidney, Reata Pharmaceuticals, Inc., Eli Lilly, KBP Biosciences, Kibow Pharma, Cincor Pharma, AstraZeneca, Lexicon Pharmaceuticals, Sanofi, Allena Pharmaceuticals, and DiaMedica Therapeutics Inc.

Scope of Report

The report addresses critical subjects such as strategic competitor evaluation, market characterization, unmet needs, and the consequences of these elements for the Chronic Kidney Disease (CKD) market. It also delves into the analysis of present and prospective market competition within the global Chronic Kidney Disease market.

Furthermore, the report offers an insightful examination of the primary industry drivers, constraints, and challenges. Each trend undergoes independent research to furnish qualitative analysis regarding its implications.

Reasons to Buy

• Develop your business strategies by gaining insights into the trends that shape and drive the Chronic Kidney Disease market across the 8MM (Eight Major Markets).
• Increase revenue by comprehending key trends, innovative products and technologies, market segments, and companies poised to influence the future of the 8MM Chronic Kidney Disease market.
• Craft effective sales and marketing strategies by thoroughly understanding the competitive landscape and analyzing the performance of various competitors.
• Identify emerging players with potentially robust product portfolios and devise strategic counter-strategies to gain a competitive advantage.
• Optimize your sales and marketing efforts by pinpointing market categories and segments that offer the greatest opportunities for consolidations, investments, and strategic partnerships.

Please note that detailed pipeline analysis can be provided along with the standard scope to assist you in developing and designing your in-licensing and out-licensing strategies. This includes a review of pipeline products and technologies, along with identifying companies with the most robust pipeline.

1. Executive Summary: Chronic Kidney Disease (CKD)
   • Global Market Outlook: Chronic Kidney Disease (CKD)
2. Competitive Intelligence Analysis: Chronic Kidney Disease (CKD)
3. Therapeutic Sector SWOT
4. Technology Roadmap Analysis: Chronic Kidney Disease (CKD)
5. Market Background
   • Drivers
   • Restraints
   • Opportunity
   • Key Market Trends
   • Key Unmet Needs
6. Disease Overview: Chronic Kidney Disease (CKD)
   • Disease Etiology
   • Pathophysiology
   • Risk Factors
   • Treatment Algorithm
7. Chronic Kidney Disease (CKD): Key Marketed Products Profile – Major Approved Products
   • Product Profile
   • Regulatory Milestones
   • Safety and Efficacy
   • Clinical Development
8. Chronic Kidney Disease (CKD): Promising Pipeline Candidates – Major Products in Late Stage of Development
   • Product Description
   • Safety and Efficacy
   • Research and Development
9. Regulatory Landscape
10. Chronic Kidney Disease (CKD): Eight Major Market (8MM) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
11. S. Chronic Kidney Disease (CKD) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
12. K. Chronic Kidney Disease (CKD) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
13. Germany Chronic Kidney Disease (CKD) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
14. France Chronic Kidney Disease (CKD) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
15. Italy Chronic Kidney Disease (CKD) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
16. Spain Chronic Kidney Disease (CKD) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
17. Japan Chronic Kidney Disease (CKD) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
18. China Chronic Kidney Disease (CKD) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
19. Competitive Landscape
    • Company Overview
    • Product Portfolio
    • Key Financials
    • Sales Footprint

Note – All Major Company Profiles (Count up to 20) will be covered in the report

20. Assumptions and Acronyms Used
21. Research Methodology
    • Secondary Research
    • Primary Research
    • Data Triangulation
22. Geographic Scope
    • The U.S., The U.K., Germany, France, Italy, Spain, Japan, and China
23. Copyrights and Disclaimer